Skip to contents

Jonathan Z. Li, MD, MMSc
Assistant Professor, Brigham and Women's Hospital
Assistant Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Infectious Diseases
75 Francis Street
Boston, MA 02115

Research Location: 65 Lansdowne Street

Research Email: jli@bwh.harvard.edu

Edit Profile


Research Narrative:

My laboratory is focused on the study of the latent HIV reservoir, predictors of post-treatment virologic control, HIV drug resistance, and minority variants.  I am the Director of the Harvard Virology Specialty Laboratory of the AIDS Clinical Trials Group (ACTG) and the Associate Director of the Harvard University Center for AIDS Research Clinical Core.  I also serve as the Deputy Editor for the IDSA journal Open Forum Infectious Diseases.


Education:
Harvard Medical School, 2012, MMS
University of California, San Francisco, 2004, MD
Brown University, 1999, BA

Publications (Pulled from Harvard Catalyst Profiles):

1. Jilg N, Li JZ. On the Road to a HIV Cure: Moving Beyond Berlin and London. Infect Dis Clin North Am. 2019 Sep; 33(3):857-868.

2. Le CN, Britto P, Brummel SS, Hoffman RM, Li JZ, Flynn PM, Taha TE, Coletti A, Fowler MG, Bosch RJ, Gandhi RT, Klingman KL, Mcintyre JA, Currier JS. Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared to men. AIDS. 2019 Aug 01.

3. Conway JM, Perelson AS, Li JZ. Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers. PLoS Comput Biol. 2019 Jul; 15(7):e1007229.

4. Etemad B, Esmaeilzadeh E, Li JZ. Learning From the Exceptions: HIV Remission in Post-treatment Controllers. Front Immunol. 2019; 10:1749.

5. Li JZ, Segal FP, Bosch RJ, Lalama CM, Roberts-Toler C, Delagreverie H, Getz R, Garcia-Broncano P, Kinslow J, Tressler R, Van Dam CN, Keefer M, Carrington M, Lichterfeld M, Kuritzkes D, Yu XG, Landay A, Sax PE. ART reduces T cell activation and immune exhaustion markers in HIV controllers. Clin Infect Dis. 2019 May 25.

6. Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. 2019 Apr; 6(4):e259-e268.

7. Li JZ, Sax PE, Marconi VC, Fajnzylber J, Berzins B, Nyaku AN, Fichtenbaum CJ, Wilkin T, Benson CA, Koletar SL, Lorenzo-Redondo R, Taiwo BO. No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial. Open Forum Infect Dis. 2019 Mar; 6(3):ofz056.

8. Einkauf KB, Lee GQ, Gao C, Sharaf R, Sun X, Hua S, Chen SM, Jiang C, Lian X, Chowdhury FZ, Rosenberg ES, Chun TW, Li JZ, Yu XG, Lichterfeld M. Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. J Clin Invest. 2019 Mar 01; 129(3):988-998.

9. Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis. 2018 Nov 05; 218(12):1954-1963.

10. Wen Y, Bar KJ, Li JZ. Lessons learned from HIV antiretroviral treatment interruption trials. Curr Opin HIV AIDS. 2018 09; 13(5):416-421.